Correspondence 0001193125-24-187542 from Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Cidara Therapeutics, Inc. (CDTX) (CIK 0001610618)
Date: July 29, 2024 · CIK: 0001610618 · Accession: 0001193125-24-187542
AI Filing Summary & Sentiment
File numbers found in text: 333-280919
Letter
Cidara Therapeutics, Inc.
6310 Nancy Ridge Drive, Suite 101
San Diego, California 92121
July 29,
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Attn: Joshua Gorsky
Re: Cidara Therapeutics, Inc. (the “Company”)
Registration Statement on Form S-1
Filed: July 19, 2024
File No. 333-280919
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective at 4:00 p.m. Eastern Time on July 31, 2024 or as soon thereafter as is practicable, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission.
Once the Registration Statement has been declared effective, please orally confirm that event with Charles J. Bair of Cooley LLP at (858) 550-6142.
Very truly yours,
CIDARA THERAPEUTICS, INC.
Show Raw Text
CORRESP 1 filename1.htm CORRESP Cidara Therapeutics, Inc. 6310 Nancy Ridge Drive, Suite 101 San Diego, California 92121 July 29, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Joshua Gorsky Re: Cidara Therapeutics, Inc. (the “Company”) Registration Statement on Form S-1 Filed: July 19, 2024 File No. 333-280919 Ladies and Gentlemen: Pursuant to Rule 461 under the Securities Act of 1933, as amended, the Company hereby requests that the U.S. Securities and Exchange Commission (the “Commission”) take appropriate action to cause the above-referenced Registration Statement on Form S-1 to become effective at 4:00 p.m. Eastern Time on July 31, 2024 or as soon thereafter as is practicable, or at such other time as its legal counsel, Cooley LLP, may request by telephone to the staff of the Commission. Once the Registration Statement has been declared effective, please orally confirm that event with Charles J. Bair of Cooley LLP at (858) 550-6142. Very truly yours, CIDARA THERAPEUTICS, INC. By: /s/ Jeffrey Stein, Ph.D. Name: Jeffrey Stein, Ph.D. Title: President and Chief Executive Officer cc: Charles J. Bair, Cooley LLP